11:54 AM EDT, 05/30/2024 (MT Newswires) -- Xeris Biopharma ( XERS ) shares climbed more than 17% in recent Thursday trading after the company said its potential levothyroxine sodium injection XP-8121 to treat adults with hypothyroidism is preferred over the oral formulation in a phase 2 trial.

The investigational treatment uses the company's XeriSol formulation technology in the once-weekly subcutaneous injection of levothyroxine, the company said.

Assessing patient satisfaction, Xeris said XP-8121 "scored consistently higher in all three domains" compared to oral levothyroxine, referring to effectiveness, convenience, and global satisfaction.

The company said 72% of the study participants indicated a strong preference for the injection route over oral administration.

Price: 2.27, Change: +0.34, Percent Change: +17.67